FDA approves Novartis’ Piqray as the first drug targeting PIK3CA mutation

5610737610_af52c6187d_z (1)
PIK3CA is the most common mutation in HR+/HER2- breast cancer and it is associated with tumour growth, resistance to endocrine treatment and poor overall prognosis. Credit: Ed Uthman via Flickr.